Myomo (MYO)
(Delayed Data from AMEX)
$4.90 USD
+0.09 (1.87%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $4.87 -0.03 (-0.61%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.90 USD
+0.09 (1.87%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $4.87 -0.03 (-0.61%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Zacks News
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Moves 5.5% Higher: Will This Strength Last?
by Zacks Equity Research
Myomo, Inc. (MYO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 17.39% and 31.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 21.28% and 14.50%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic
by Zacks Equity Research
Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe
by Zacks Equity Research
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.
Boston Scientific (BSX) Hurt by Product Recall, Conversion
by Zacks Equity Research
Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
by Zacks Equity Research
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance
by Zacks Equity Research
Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.
Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout
by Zacks Equity Research
Hill-Rom's (HRC) acquisition of Bardy Diagnostics enables the former to expand into ambulatory cardiac monitoring space to accelerate digital health offering.
3 Beaten-Down MedTech Stocks Set to Stage a Comeback in 2021
by Sriparna Ghosal
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 14.50% and 43.17%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -29.38% and 29.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -7.37% and 8.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Myomo, Inc. (MYO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Myomo, Inc. (MYO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Rides on New Product Portfolio, SaaS Growth
by Zacks Equity Research
Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.
Here's Why You Should Add ResMed (RMD) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.
QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe
by Zacks Equity Research
QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.
ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.
Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark
by Zacks Equity Research
Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.
Align (ALGN) Rides on Volume Expansion Despite Cost Concerns
by Zacks Equity Research
We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.